All Episodes

S19 Ep13: Beyond PD-L1: Refining First-Line Treatment Decisions in Metastatic NSCLC

S19 Ep12: Order Both IHC and NGS: Defining MET Alterations and Positioning Telisotuzumab Vedotin in Non–Small Cell Lung Cancer

S19 Ep11: Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape

S19 Ep10: FDA Approval Insights: First-Line Maintenance Tucatinib/Trastuzumab/Pertuzumab in Advanced HER2+ Breast Cancer

S19 Ep9: Biology-Driven Care and AI Tools Steer the Future of Breast Oncology

S19 Ep8: Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma

S19 Ep7: Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers

S19 Ep6: The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer

S19 Ep5: Navigating Patient-Centric Treatment Administration Strategies in Myeloma

S19 Ep4: Novel MEK inhibitor Research Aims to Balance Efficacy and Tolerability in Pancreatic Cancer

S19 Ep3: FDA Approval Insights: Ropeginterferon Alfa-2b Ushers in Long-Awaited New Treatment Option for Essential Thrombocythemia

S19 Ep2: FDA Approval Insights: Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma

S19 Ep2: Resistance Patterns Shape FGFR Inhibitor Sequencing in Cholangiocarcinoma

S19 Ep1: Subcutaneous Therapies Bolster Administration Options in Multiple Myeloma

S18 Ep50: Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape

S18 Ep49: Start Earlier and Find Your Community: Navigating the Fellowship-to-Faculty Transition Through Mentorship and Specialty-Focused Meetings

S18 Ep48: OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma

S18 Ep47: Dissecting Diagnostic and Management Factors in Systemic Mastocytosis

S18 Ep46: Unpacking Data and Upcoming Developments for Olverembatinib in CML

S18 Ep45: Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

S18 Ep44: Exploring the FDA Approval of Optune Pax and What It Means for Locally Advanced Pancreatic Cancer

S18 Ep43: Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

S18 Ep42: Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer

S18 Ep41: Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC

S18 Ep40: INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

S18 Ep39: Pancreatic Cancer Experts Map Treatment Sequencing With Liposomal Irinotecan and Beyond

S18 Ep34: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma—Testing, Treatment, and Supportive Care

S18 Ep38: Fast-Moving Treatment Advances Shape B-Cell Lymphoma Care

S18 Ep37: Metastatic Non-Small Cell Lung Cancer 2026 UPDATE

S18 Ep36: Precision Immunotherapy, PET-Adapted Regimens, and Novel Targets Are Redefining Hodgkin Lymphoma Care: With Chandler Park, MD; Joshua Brody, MD

S18 Ep35: The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing

S18 Ep33: Current Approaches and Future Directions for Early-Stage TNBC

S18 Ep32: Non–Small Cell Lung Cancer 2026 UPDATE

S18 Ep31: FDA Approval Insights: Integrating RP1 Plus Nivolumab Into Post–PD-1 Melanoma Practice: With Michael K. Wong, MD, PhD, FRPC

S18 Ep31: Immunotherapy Decision-Making in CSCC Sits at the Intersection of Efficacy and Comorbidity: With Eric D. Whitman, MD; and Francis Paul Worden, MD

S18 Ep30: FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO

S18 Ep29: 𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

S18 Ep28: Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD

S18 Ep27: Key Considerations for Health Equity and Patient-Centered Care in TNBC

S18 Ep26: FDA Approval Insights: Gedatolisib Plus Fulvestrant ± Palbociclib for HR+, HER2-Negative, PIK3CA Wild-Type Advanced Breast Cancer: With Adam M. Brufsky, MD, PhD

S18 Ep25: Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

S18 Ep24: Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

S18 Ep23: From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC

S18 Ep22: FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

S18 Ep21: Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

S18 Ep20: Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

S18 Ep19: Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

S18 Ep18: Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

S18 Ep17: Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD

S18 Ep16: FDA Approval Insights: Orca-T Raises the Bar for Allogeneic Transplants in Hematologic Malignancies: With Everett Meyer, MD, PhD

S18 Ep15: ASCO 2026 ADC Data Clarify Some Strategies and Raise Further Questions for Breast Cancer Care: With Paolo Tarantino, MD, PhD

S18 Ep14: FDA Approval Insights: First-Line Sacituzumab Govitecan Plus Pembrolizumab for PD-L1+ TNBC: With Sara M. Tolaney, MD, MPH

S18 Ep13: FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Jorge E. Cortes, MD; and Elias Jabbour, MD

S18 Ep12: Treat Early and Aggressively: Optimizing Small Cell Lung Cancer Management Across the Community Setting: With Joshua Sabari, MD

S18 Ep11: Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

S18 Ep10: Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

S18 Ep9: ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

S18 Ep8: DLBCL 2026 UPDATE

S18 Ep7: Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

S18 Ep6: Navigating Systemic Therapy Selection and Sequencing in Advanced CSCC: With Neil D. Gross, MD, FACS

S18 Ep5: Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

S18 Ep4: Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

S18 Ep3: Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us

S18 Ep2: Cases and Conversations™: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

S18 Ep1: RECITE Findings Highlight the Potential of Romiplostim to Preserve Chemotherapy Delivery in GI Cancer: With Gerald Soff, MD

S17 Ep50: Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

S17 Ep49: Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

S17 Ep48: FDA Approval Insights: Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma: With Alex Herrera, MD

S17 Ep47: Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

S17 Ep46: ESR1 Mutations Steer the Oral SERD Story in Breast Cancer: With Sara Nunnery, MD, MSCI; and MinhTri Nguyen, MD

S17 Ep45: Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

S17 Ep43: FDA Approval Insights: T-DXd for Early-Stage HER2+ Breast Cancer: With Charles E. Geyer, MD

S17 Ep42: Treatment Intensification in Vulnerable Populations: ARPI Use in Elderly, Frail, and High-Comorbidity Patients With mCSPC: With Martin Schoen, MD, and Andrew W. Hahn, MD

S17 Ep41: Dissecting INDEPENDENCE Data and the Role of Luspatercept in Myelofibrosis-Associated Anemia: With Claire Harrison, MD

S17 Ep44: SERENA-6 Splits the Breast Cancer Field on Switching Therapy Before Radiographic Progression: With Sara Nunnery, MD, MSCI; and Megan Kruse, MD

S17 Ep40: Medical Crossfire®: Turning Therapeutic Innovation Into Practice—Personalizing Care in Multiple Myeloma

S17 Ep39: Sequencing and Emerging Targets Revamp the Platinum-Resistant Ovarian Cancer Treatment Paradigm: With David O’Malley, MD

S17 Ep38: FDA Approval Insights: Decitabine/Cedazuridine Plus Venetoclax for AML: With Courtney D. DiNardo, MD, MSCE

S17 Ep37: Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

S17 Ep72: Quadruplet Regimens and T-Cell Redirection Are on the Map of Myeloma Management Strategies: With Chandler Park, MD; Muhamed Baljevic, MD, FACP

S17 Ep36: FDA Approval Insights: Orally Disintegrating Nilotinib Tablets for CML: With Michael J. Mauro, MD

S17 Ep35: KRAS-Directed Therapy Enters a New Era in Pancreatic Cancer: With Zev A. Wainberg, MD

S17 Ep34: As CTCL Staging and Treatment Evolves, Treatment-Associated Rash Remains a Crucial Consideration: With Brad Haverkos, MD

S17 Ep44: Oral SERDs Transform Metastatic Breast Cancer Management: With Sara Nunnery, MD, MSCI; and Vandana G. Abramson, MD

S17 Ep33: Oncology Town Hall: Updates From Berlin: Oral SERDs in HR+/HER2– Metastatic Breast Cancer — What the Latest Data Really Tell Us

S17 Ep72: ADCs, Metabolic Health Strategies, and Lifestyle Interventions Add up to Holistic TNBC Care: With Chandler Park, MD; and Neil M. Iyengar, MD

S17 Ep32: Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD

S17 Ep31: ASCO 2026 Plenary: RASolute 302

S17 Ep30: Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy

S17 Ep29: Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD

S17 Ep28: In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD

S17 Ep27: Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD

S17 Ep26: Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

S17 Ep25: TKIs Continue to Move Forward and Expand Their Potential in CML: With Michael J. Mauro, MD

S17 Ep24: Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD

S17 Ep22: Answering Key Clinical Questions About Esophageal Cancer Care: With Peter Enzinger, MD

S17 Ep23: FDA Approval Insights: Brexu-Cel for Relapsed/Refractory MCL: With Luhua (Michael) Wang, MD

S17 Ep21: Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond

S17 Ep20: Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD

S17 Ep19: Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer